Christine Chung L.
Corporate Officer/Principal bij FIBROGEN, INC.
Vermogen: 209 460 $ op 30-04-2024
Actieve functies van Christine Chung L.
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
FIBROGEN, INC. | Corporate Officer/Principal | 01-01-2007 | - |
FibroGen (China) Medical Technology Development Co. Ltd.
FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The private company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Chief Executive Officer | 01-01-2019 | - |
Beijing Falikang Pharmaceutical Co. Ltd.
Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | Chairman | 27-09-2020 | - |
FibroGen International (Hong Kong) Ltd. | Director/Board Member | 01-01-2018 | - |
FibroGen International (Cayman) Ltd. | Director/Board Member | 01-01-2019 | - |
Loopbaan van Christine Chung L.
Eerdere bekende functies van Christine Chung L.
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
eMed Technologies Corp.
eMed Technologies Corp. Packaged SoftwareTechnology Services eMed Technologies Corp. developed medical software technologies. It combined PACS, image management, web-based results distribution and web communications into a solution that empowered radiologists to manage more procedures, improve service and gain a competitive edge. It was headquartered in Burlington, MA. | Corporate Officer/Principal | - | - |
Opleiding van Christine Chung L.
Harvard University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 4 |
China | 3 |
Kaaimaneilanden | 2 |
Operationeel
Corporate Officer/Principal | 2 |
Director/Board Member | 2 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 4 |
Technology Services | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
FIBROGEN, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
eMed Technologies Corp.
eMed Technologies Corp. Packaged SoftwareTechnology Services eMed Technologies Corp. developed medical software technologies. It combined PACS, image management, web-based results distribution and web communications into a solution that empowered radiologists to manage more procedures, improve service and gain a competitive edge. It was headquartered in Burlington, MA. | Technology Services |
FibroGen (China) Medical Technology Development Co. Ltd.
FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The private company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Health Technology |
FibroGen International (Cayman) Ltd. | |
FibroGen International (Hong Kong) Ltd. | |
Beijing Falikang Pharmaceutical Co. Ltd.
Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | Health Technology |
- Beurs
- Insiders
- Christine Chung L.
- Ervaring